Default company panoramic image
Logo

Altheus Therapeutics, Inc.

Altheus is entering Phase 2 clinical trials with Zoenasa, a novel front-line combination treatment for ulcerative colitis.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Oklahoma City, OK, USA
  • Currency USD
  • Founded August 2007
  • Employees 9
  • Website altheustherapeutics.com

Company Summary

Altheus Therapeutics is developing Zoenasa as an innovative treatment for ulcerative colitis to meet the strong medical need for new therapies in this area. To build on its successful Phase 1 trial with Zoenasa, Altheus is raising $8 million to complete a Phase 2 proof-of-concept study and other development activities that will position the company for a joint-development agreement with a larger company and potential liquidity event.

Team

  • Default avatar
    Dennis P Schafer
    President & Chief Executive Officer

    An accomplished entrepreneur with 25 years’ experience in organizing and managing life science start-ups, Mr. Schafer has played leadership roles in a dozen start-ups, including BioCryst Pharmaceuticals, Coley Pharmaceuticals, and Aderis.

  • Default avatar
    Richard F Harty
    Founder & Chief Science Officer

    The former Chief of Gastroenterology at the OU Health Sciences Center, Dr. Harty is an internationally recognized practitioner, educator, and researcher.

  • Default avatar
    Dayton T Reardan
    Chief Operating Officer

    Former VP Regulatory Affairs at Orphan Medical, Dr. Reardan is nationally recognized for his expertise in developing orphan drugs and other products with abbreviated development paths.

Advisors

  • Default avatar
    Douglas A. Branch, JD (Phillips Murrah)
    Lawyer
    Unconfirmed
    Default avatar
    Cindy Sewell Dunlop; Cole & Reed
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Prolog Ventures, i2e Seed Fund,
    Unconfirmed
    Default avatar
    Oklahoma Life Sciences Fund II,
    Unconfirmed
    Default avatar
    Oklahoma Equity Partners, Chickasaw Soliris,
    Unconfirmed